QURE
HEALTHCAREuniQure N.V.
$22.82+1.66 (+7.84%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving QURE Today?
No stock-specific AI insight has been generated for QURE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.73$71.50
$22.82
Fundamentals
Market Cap$1.4B
P/E Ratio—
EPS$-3.49
Dividend Yield—
Dividend / Share—
ROE-2.1%
Profit Margin—
Debt / Equity—
Trading
Volume3.6M
Avg Volume (10D)—
Shares Outstanding63.1M
QURE News
44 articles- uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest ReportYahoo Finance·May 8, 2026
- Oncolytics Biotech Reports Data in Colorectal Cancer StudyYahoo Finance·May 6, 2026
- uniQure Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- uniQure (QURE) Reports Q1 Loss, Misses Revenue EstimatesYahoo Finance·May 5, 2026
- uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company UpdatesYahoo Finance·May 5, 2026
- How The uniQure (QURE) Investment Story Is Shifting With AMT-130 And Regulatory UncertaintyYahoo Finance·May 4, 2026
- uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment CaseYahoo Finance·May 4, 2026
- Sector Update: Health Care Stocks Gain Late AfternoonYahoo Finance·Apr 30, 2026
- uniQure Announces Successful UK MHRA Pre-Submission Meeting for AMT-130 in Huntington’s DiseaseYahoo Finance·Apr 30, 2026
- uniQure to Announce First Quarter 2026 Financial ResultsYahoo Finance·Apr 28, 2026
- uniQure N.V. (QURE) Stock Posts 30% Growth from Last YearYahoo Finance·Apr 22, 2026
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire Inc.·Apr 13, 2026
- INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 10, 2026
- INVESTOR DEADLINE: uniQure (QURE) Investors with Substantial Losses Have Opportunity to Lead the uniQure Class Action Lawsuit– Hagens BermanGlobeNewswire Inc.·Apr 8, 2026
- uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 8, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in AMC Entertainment Holdings, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMC; APEGlobeNewswire Inc.·Apr 7, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QUREGlobeNewswire Inc.·Apr 7, 2026
- ROSEN, A LEADING NATIONAL FIRM, Encourages Trip.com Group Limited Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TCOMGlobeNewswire Inc.·Apr 6, 2026
- UNIQURE DEADLINE: ROSEN, A LEADING AND LONGSTANDING FIRM, Encourages uniQure N.V. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QUREGlobeNewswire Inc.·Apr 6, 2026
- INO FINAL DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Inovio Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action – INOGlobeNewswire Inc.·Apr 6, 2026
- Is Regulatory Scrutiny of AMT-130 Quietly Rewriting uniQure’s (QURE) Gene Therapy Investment Story?Yahoo Finance·Apr 5, 2026
- QURE 9-DAY DEADLINE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” DataGlobeNewswire Inc.·Apr 4, 2026
- UNIQURE DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages uniQure N.V. Investors to Secure Counsel Before Important April 13 Deadline in Securities Class Action - QUREGlobeNewswire Inc.·Apr 2, 2026
- UNIQURE DEADLINE APPROACHING: Bragar Eagel & Squire, P.C. Encourages uniQure N.V. Stockholders with Large Losses to Contact the Firm Before April 13thGlobeNewswire Inc.·Apr 2, 2026
- Barclays Reaffirms Equal Weight Rating for uniQure (QURE)Yahoo Finance·Apr 1, 2026
- uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLCGlobeNewswire Inc.·Apr 1, 2026
- INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines – QUREGlobeNewswire Inc.·Mar 31, 2026
- Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. InvestorsGlobeNewswire Inc.·Mar 31, 2026
- QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law FirmBenzinga·Mar 30, 2026
- ROSEN, A TRUSTED AND LEADING INVESTOR RIGHTS FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QUREGlobeNewswire Inc.·Mar 29, 2026
- QURE ALERT: Hagens Berman Updates uniQure (QURE) Investigation Following Public FDA Rebukes and Allegations of “Distorted” DataGlobeNewswire Inc.·Mar 27, 2026
- QURE Shareholder Alert: uniQure N.V. Securities Class Action Lawsuit Investors With Losses May Join — The Gross Law FirmGlobeNewswire Inc.·Mar 27, 2026
- Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?Yahoo Finance·Mar 26, 2026
- uniQure Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against uniQure N.V. - QUREGlobeNewswire Inc.·Mar 26, 2026
- Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?Yahoo Finance·Mar 18, 2026
- uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts247 Wall St·Mar 9, 2026
- uniQure stock surges 36% on FDA official’s departureYahoo Finance·Mar 9, 2026
- Shifting Narrative For uniQure (QURE) As FDA Trial Demands Reshape AMT-130 ExpectationsYahoo Finance·Mar 8, 2026
- QURE Stock Crashes 32% in a Week: Here's What You Should KnowYahoo Finance·Mar 6, 2026
- uniQure (QURE) Loses 67.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerYahoo Finance·Mar 4, 2026
Price Data
Open$20.97
Previous Close$21.16
Day High$23.17
Day Low$20.50
52 Week High$71.50
52 Week Low$8.73
52-Week Range
$8.73$71.50
$22.82
Fundamentals
Market Cap$1.4B
P/E Ratio—
EPS$-3.49
Dividend Yield—
Dividend / Share—
ROE-2.1%
Profit Margin—
Debt / Equity—
Trading
Volume3.6M
Avg Volume (10D)—
Shares Outstanding63.1M
About uniQure N.V.
uniQure NV, a gene therapy company, is dedicated to developing treatments for patients suffering from genetic and other devastating diseases. The company is headquartered in Amsterdam, the Netherlands.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—